CDSCO initiates joint audit of Indian cough syrup manufacturers following DEG contamination reports
The Central Drugs Standard Control Organisation (CDSCO) has ordered a joint audit of cough syrup manufacturers across India. This regulatory action follows the identification of three contaminated syrups—Coldrif, Respifresh, and Re-Life—containing diethylene glycol (DEG), which have been linked to child deaths. While these products were marketed domestically and not exported, the WHO has flagged a 'regulatory gap' in screening for DEG and ethylene glycol (EG) in India. The audit aims to identify manufacturers, stop production of unsafe medical products, and tighten domestic quality control standards in the pharmaceutical industry.
Key Points
- Diethylene glycol (DEG) is a highly toxic contaminant that can cause kidney failure and death.
- The CDSCO is working with State governments to create a comprehensive list of all domestic cough syrup makers.
- The World Health Organization (WHO) is supporting Indian authorities in investigating the source of contamination.
- The incident highlights the need for more rigorous screening of raw materials and solvents used in pharmaceutical manufacturing.
Exam Facts
- CDSCO: Central Drugs Standard Control Organisation.
- Contaminants: Diethylene glycol (DEG) and Ethylene glycol (EG).
- Syrups identified: Coldrif, Respifresh, and Re-Life.
- WHO flagged regulatory gaps in domestic DEG/EG screening.
Read it. Retain it. Recall it.
Get spaced-repetition flashcards, daily quizzes and offline access — free on Android.